Drug firms await India court decision on patent protection

03/27/2013 | Economic Times (India), The

Pharmaceutical companies are awaiting a decision from India's Supreme Court, due April 1, that could determine the state of intellectual property protection for branded drugs in India. The case involves whether an amended form of Novartis' cancer treatment Glivec, used to treat chronic myeloid leukemia, is entitled to patent protection against generic competitors. "Big Pharma is nervous because nothing has gone in their favour in the recent past," said pharmaceutical consultant Ajay Kumar Sharma.

View Full Article in:

Economic Times (India), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD